Log-in / Create Account  
The 22nd Annual North American CF Conference Session List
Click here to search this conference.
Display sessions grouped by:
Track Session Code Speaker Date

Track: 

Complete Conference Online Access Set - Days 1-3 (Streaming Audio Synchronized to PowerPoint)
Special Educational Online Access Set - SHORT COURSES (Streaming Audio Synchronized to PowerPoint)
Special Online Access by Day (Streaming Audio Synchronized to PowerPoint)
October 22, 2008
October 23, 2008
October 24, 2008
October 25, 2008
Demo
 

Complete Conference Online Access Set - Days 1-3 (Streaming Audio Synchronized to PowerPoint)

SET  Complete Conference Online Access Set - Days 1-3 
Back to Top
Special Educational Online Access Set - SHORT COURSES (Streaming Audio Synchronized to PowerPoint)

SC  Special Educational Online Access - SHORT COURSES 
Back to Top
Special Online Access by Day (Streaming Audio Synchronized to PowerPoint)

DY1  Day 1 - Thursday, October 23, 2008 
DY2  Day 2 - Friday, October 24, 2008 
DY3  Day 3 - Saturday, October 25, 2008 
Back to Top
October 22, 2008

SC01  Learning and Experiencing Complementary Therapy Practices for Achieving Comfort, Fortitude, and Well-being in CF Care 
SC01-01  Overview of Complementary/Alternative Medicine (CAM)   
SC01-02  Mind Body Medicine   
SC01-03  Qi Gong   
SC01-04  Hypnotherapy   
SC01-05  IMPROVING WELL-BEING IN CF PATIENTS WITH YOGA   
SC01-06  Introduction to Energy Psychology (EFT) and its potential applications for CF patients and their caregivers   
SC01-07  The Consumer's Experiences and Perspective about Complementary and Alternative Approaches   
SC02  Taking CF Nutrition to the Next Level: Advanced Concepts and Practical Applications 
SC02-01  Taking CF Nutrition to the Next Level: Advanced Concepts and Practical Applications   
SC02-02  Gastrointestinal Issues in CF   
SC02-03  CF-related osteoporosis   
SC02-04  CF, Nutrition & Pregnancy   
SC02-05  Nutritional implications of lung transplantation in CF   
SC02-06  Nutrition and Quality Improvement   
SC03  The "Ins and Outs" of CF Respiratory Management: Beyond the Basics for the Advanced Practice Nurse 
SC03-01  The "In's and Out's" of CF Respiratory Management: Beyond the Basics for the Advanced Practice Nurse   
SC03-02  Monitoring and Treatment of CF Lung Disease   
SC03-03  THE DEVELOPING CF LUNG: INFANTS AND CHILDREN   
SC03-04  The Adult with Cystic Fibrosis: Rescue Treatment and Management of Complications   
SC04  The CF Family Education Program: Self-management for People with CF and Their Families 
SC04-01  The CF Family Education Program: Self-Management for People with CF & Their Families   
SC04-02  The New and Improved CF Family Education Program   
SC04-03  Watch, Discover, Think and Act: Concepts within the CF FEP   
SC04-04  Managing Lung Problems and the CF FEP   
SC04-05  Managing Nutrition & Digestion Problems and the Cystic Fibrosis Family Education Program   
SC04-06  Working with Children: Cooperation, Communication, and Choices   
SC04-07  Transitioning Self Management to Teens   
SC04-08  Using the CF FEP Program in a Busy CF Center: Top Ten Tips   
SC05  Diagnosing and Managing Gastrointestinal Disease in CF 
SC05-01  Normal gastrointestinal function   
SC05-02  Normal Gastrointestinal Function The Exocrine Pancreas   
SC05-03  Hepatobiliary Function: Normal Physiology   
SC05-04  Abdominal Pain in Cystic Fibrosis Patients   
SC05-05  Upper GI Tract in CF   
SC05-06  Meconium Ileus, Constipation and Distal Intestinal Obstruction Syndrome   
SC05-07  HEPATOBILIARY DISEASE IN CYSTIC FIBROSIS   
SC05-08  Nutrition and Enzyme Replacement Therapy   
SC05-09  Exocrine Pancreas in CF   
SC06  Creating a Culture of Research 
SC06-01  Creating a Culture of Research Through Leadership   
SC06-02  The Proof Is In The Pudding: Lessons Learned   
SC06-03  The Business of Clinical Research   
SC06-04  Creating a Culture of Research   
SC07  Strengthening Adult CF Programs 
SC07-01  The CFF and Adult CF Programs   
SC07-02  BUILDING A GREAT ADULT PROGRAM AND A GREAT RELATIONSHIP WITH YOUR PEDIATRIC CENTER   
SC07-03  Show me the Money: CF Finances to assist your program   
SC07-04  Barriers to Adequate Nutrition in Adult CF   
SC07-05  CFF Guideline Review   
Back to Top
October 23, 2008

P1  Preventing CF Lung Disease     
S01  Controversies in Infection Control   
S01-01  Doctor, What Should I Do?     
S01-02  Bacterial Contamination of CF Clinics     
S01-03  The European Experience     
S01-04  The Changing Epidemiology of MRSA in CF     
S02  What Can PT Do for Your CF Clinic? Posture, Pain, Pelvic Floor, and More   
S02-01  Benefits and Challenges of Integrating PT in CF Clinic - A CF Center Director's Perspective     
S02-02  Rewards and Challenges of Integrating PT in CF Clinic - A Physical Therapist's Perspective     
S02-03  Referred by the CF Clinic's PT: Treatment of Posture and Pain     
S02-04  Cough and the Pelvic Floor: Prevent, Control and Treat Urinary Incontinence     
S03  Emerging Endpoints to Predict Success of CF Clinical Trials   
S03-02  Aerosol-based Methods of Assessing Mucociliary Clearance     
S03-03  Multiple Breath Washout - a Clinician's Perspective     
S03-04  Patient Related Outcomes     
S04  Google Map to the Membrane: Protein Interactions in CFTR Traffic   
S04-01  Dynamic Chaperone Interactions Mediate CFTR Conformational Maturation     
S04-02  PDZ Proteins as Therapeutic Targets for CF: A CAL-Selective Inhibitor Increases Functional Levels of ΔF508-CFTR     
S04-03  Molecular Aspects of Non-native CFTR Elimination from the Cell Surface     
S04-04  P. aeruginosa Affects Endocytic Trafficking of CFTR in Human Airway Epithelial Cells     
S05  Gastrointestinal Problems in CF   
S05-01  Basic Science: Small Bowel Overgrowth and Mucosal Disease in CF Mouse     
S05-02  Clinical Diagnosis and Management of Small Bowel Overgrowth in CF     
S05-03  DIOS and Constipation in CF     
S05-04  Probiotics in Cystic Fibrosis: Help from Old Friends     
S06  Airway Innervation & Coughing   
S06-01  Overview of Airway Innervation     
S06-02  Vagal Afferent Innervation of the Airways in Health and Disease     
S06-03  Function of the Airway Parasympathetic Nervous System   
S06-04  Neural Control of Cough     
S07  Key Issues in Lung Transplantation for CF   
S07-01  Impact of the UNOS Lung Allocation System on Patients with CF     
S07-02  Can Children with CF Benefit from Lung Transplantation?     
S07-03  Is Lung Transplantation Appropriate for Patients with B. Cepacia Complex or Pan-resistant Organisms?     
S07-04  Progress and Strategies Towards Reducing Complications and Improving Lung Transplant Outcomes     
W01  Modifier Genes   
W01-01  Abstract 197. Restoration of the CFTR Function by Splicing Modulation     
W01-02  Abstract 198. Baobab is a Regulator of CFTR-dependent Fluid Secretion 
W01-03  Abstract 199. Analysis of Genetic Modifiers of Phenotypic Severity in the Beta-ENaC Mouse Model of Cystic Fibrosis     
W01-04  Abstract 200. Variability in Body Mass Index in Cystic Fibrosis is Determined Partly By a Genetic Locus on Chromosome 5     
W01-05  Abstract 201. Variants in CAST, The Gene Encoding Calpastatin Associate with Variation in Cystic Fibrosis Lung Function     
W01-06  Abstract 202. Modifier Gene Loci for Meconium Ileus Map to Chromosomes 12 and 4     
W02  CFTR 2008 - Introduction     
W02-01  Abstract 1. Structural Changes upon Phosphorylation of CFTR: Detection by Electron Microscopy and Single Particle Analysis     
W02-02  Abstract 2. Multiple Membrane-Cytoplasmic Domain Contacts in CFTR     
W02-03  Abstract 3. In Vitro CFTR-NBD1-based Folding Assays for Assessment of Stabilizing Ligands     
W02-04  Abstract 5. Monomeric CFTR in Cell Membranes Revealed by Single-molecule Fluorescence Imaging     
W02-05  Abstract 6. Modulation of Apical Stability of Rescued ΔF508 CFTR in Primary Human Airway Epithelial Cells     
W02-06  Abstract 7. Species-specific Differences in CFTR Processing     
W02-07  Discussion & Wrap-up   
W03  Micronutrients with a Macro Punch: Update on Vitamins & Minerals in CF Care     
W03-01  Iron and CF: Deficiency and Supplementation     
W03-02  Abstract 604. Vitamin A Supplementation and Serum Vitamin A Levels in Pregnant Women with Cystic Fibrosis     
W03-03  Abstract 605. Evaluation of Ergocalciferol, Cholecalciferol or UVB Light Therapy to Improve Vitamin D Status in Cystic Fibrosis: A Prospective Randomized Study     
W03-04  Abstract 606. The Effect of Vitamin K Supplementation on Bone Status in Children with Cystic Fibrosis     
W03-05  Abstract 607. Is Urine Sodium a Good Measure of Sodium Status in Newborn Screened Infants with Cystic Fibrosis?     
W04  The CF Plan of Care — From Telephone Triage to the Inpatient Stay 
W04-01  Telephone Triage: Standardizing the Process     
W04-02  Patient Knowledge of Plan of Care: Assessment and Intervention     
W04-03  The Body Check: A New Self Assessment Tool with Multiple Functions     
W04-04  Inpatient Care: Teaching Others to Care Like You Do     
W05  Progress in Development & Maintenance of Parent & Family Involvement & Advisory Boards 
W05-01  Introduction   
W05-02  Activating People with CF and Families: Involvement at a New Level     
W05-03  Getting All the Players in the Game: Improving CF Care with Patients and Families     
W05-04  How FABulous: Creatively Connecting Families to the CF Care Center     
W05-05  Parents as Team Members - The Evolution of the Parent Advisory Committee at the UAB/Children's Hospital CF Center     
W05-06  Patient and Family Advisory Board: The Madison Wisconsin Experience     
W05-07  Circle for Life: Support Group for Women Touched by Cystic Fibrosis     
W05-08  Discussion & Wrap-up   
W06  New Therapeutic Approaches: CF Science Directed Towards Intervention 
W06-01  Introduction     
W06-02  Abstract 266. PTC124 Induces Time-Dependent Improvements in Chloride Conductance and Clinical Parameters in Patients with Nonsense-Mutation-Mediated Cystic Fibrosis     
W06-03  Abstract 267. Interim Results of Phase 2a Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis Subjects with G551D     
W06-04  Abstract 268. Correction of Sodium Transport with Nasal Administration of the Prostasin Inhibitor QAU145 in CF Subjects     
W06-05  Abstract 270. The Novel Long Acting ENaC Blocker PS643 Has Therapeutic Effects in Chronic Cystic Fibrosis-Like Lung Disease in Mice     
W06-06  Abstract 271. Lead Optimization of AAV6.2 for Treatment of Cystic Fibrosis Lung Disease     
W06-07  Abstract 272. Pulmonary Transduction in Nonhuman Primates by HDAd: Duration of Transgene Expression and Vector Re-Administration   
W06-08  Discussion & Wrap-up     
W07  Exercise Studies in CF 
W07-01  Introduction     
W07-02  Abstract 508. A "Normal" FEV1 is a Poor Predictor of Exercise Tolerance in Individuals with Cystic Fibrosis.     
W07-03  Abstract 509. Health Related Fitness and Effects of an Exercise Training Program in Patients with CF in Consideration of Severity of Disease     
W07-04  Abstract 510. Efficacy of a Standardized Exercise Protocol in Inpatient Care of Patients with Cystic Fibrosis     
W07-05  Abstract 511. The Effect of Individualized Coaching on Physical Activity Levels and Quality of Life in Children with Cystic Fibrosis     
W07-06  Abstract 512. Long-Term Effects of a 6-Month Home-Based Non-Supervised Physical Conditioning Program in Cystic Fibrosis     
W07-07  Discussion & Wrap-up     
W08  Old Pathogens, New Therapies 
W08-01  Introduction     
W08-02  Abstract 331. CF Patients and Their Household Members Share Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains     
W08-03  Abstract 332. Age of Pseudomonas aeruginosa Infection and Severity of Adult Lung Disease in Cystic Fibrosis     
W08-04  Abstract 333. Early Eradication Therapy for Pseudomonas aeruginosa and Associated Pseudomonas Antibody Levels     
W08-05  Abstract 334. Short and Long-Term Efficacy of Inhaled Tobramycin in Early P. aeruginosa Infection: The ELITE Study     
W08-06  Abstract 335. Sustained Improvement in Pulmonary Function Following a 28-Day Course of 75 mg AZLI TID Therapy     
W08-07  Abstract 337. A Phase 1 Open Label Trial to Assess the Safety and Tolerability of Fosfomycin/ Tobramycin for Inhalation in Subjects with CF or Bronchiectasis     
W09  Airway Epithelial Biology & CF Defense 
W09-01  Introduction     
W09-02  Abstract 82. Oxidative Stress by Pyocyanin Inhibits Cl Transport in Cystic Fibrosis Bronchial Epithelial Cells Corrected by Wildtype CFTR     
W09-03  Abstract 83. Interleukin-17A Induces Bicarbonate Secretion in Normal Human Bronchial Epithelial Cells     
W09-04  Abstract 84. SLC26A9 is a Constitutively Active, CFTR-Regulated Anion Conductance in Human Bronchial Epithelial Cells     
W09-05  Abstract 85. Prostagladin E2-Mediated Fluid Secretion is Partially Preserved in CF Airway Submucosal Gland     
W09-06  Abstract 86. Autocrine Loop in Purinergic Control of Airway Surface Liquid Volume: Monitoring With a Novel Side-View Imaging Technique     
W09-07  Abstract 87. Amiloride Enhances the Lung Fluid Signal Induced by Hypertonic Saline in the Rat Airways Measured Using Magnetic Resonance Imaging (MRI)     
W10  Diagnosis of CF & Identification of CF-related Diseases 
W10-01  Introduction     
W10-02  Abstract 203. Consistent Incidence of Cystic Fibrosis in a Long Term Newborn Screen Population     
W10-03  Abstract 204. Atypical CF: Clinical Characterization and Long Term Follow-Up     
W10-04  Abstract 205. Mutations in the Amiloride-Sensitive Epithelial Sodium Channel in Patients with Cystic Fibrosis-Like Disease   
W10-05  Abstract 207. The Role of F508C in Congenital Bilateral Absence of the Vas Deferens     
W10-06  Abstract 209. Ex Vivo Chloride Channel Function In Human Rectal Biopsies for Age-Independent Diagnosis and Characterisation of "Nonclassic" Cystic Fibrosis     
W10-07  Early Diagnosis of CF in a New Era with Revised CFF Diagnostic Criteria Linked to Newborn Screening     
W11  QI: The Measurements Matter 
W11-01  Introduction   
W11-02  Abstract 571. Best Practices in Promoting Patient/Family Treatment Adherence: How Are We Doing?     
W11-03  Abstract 572. Use of a Nutrition Assessment Score: Implications for CF Care     
W11-04  Abstract 573. Getting the Bugs Out: Culture Based Scheduling in the Cystic Fibrosis Outpatient Clinic     
W11-05  Abstract 574. Insurance Access Options     
W11-06  Abstract 575. Prospective Evaluation of the Delivery of Intravenous Antibiotics During CF Exacerbations     
W11-07  Abstract 576. Insights from the Adult CF Benchmarking Questionnaire     
W11-08  Discussion & Wrap-up   
Back to Top
October 24, 2008

P2  The CFF Pipeline: The Amazing Story of Progress, Hope, and Challenge     
S08  Sexuality & Fertility Issues for Adolescents & Adults with CF: New Developments   
S08-01  Pregnancy in Women with Cystic Fibrosis     
S08-02  Male Infertility in Cystic Fibrosis: What Parents Think and Say     
S08-03  A Multicenter Study of Men with CF: Lessons For Pediatric & Adult Services     
S08-04  New Developments in the Treatment of Male Infertility     
S09  Pulmonary Exacerbation: Mastering the Puzzle 
S09-01  Pulmonary Exacerbations in CF: What Are They, and Does Using a Standard Definition Improve Outcomes?     
S09-02  Evidence Based Guidelines for the Treatment of Pulmonary Exacerbations     
S09-03  Antibiotic Therapy: Essential Pieces of the Puzzle     
S09-04  Completing the Puzzle: Psychosocial Perspectives     
S10  Building the CF Therapeutic Pipeline 
S10-01  Structure-aided ΔF508 CFTR Corrector Development     
S10-02  Novel Small Molecule Correctors of ΔF508 CFTR     
S10-03  Correctors of the ΔF508 CFTR Trafficking Defect     
S10-04  Repair of CFTR Folding Defects Using Pharmacological Chaperones     
S11  Antimicrobial Susceptibility Testing 
S11-01  Potential Utility of Synergy Testing in CF     
S11-02  Clinical Evidence for Combination Antibiotic Susceptibility Testing (Synergy Testing)     
S11-03  Biofilm Susceptibility Testing: Does it Have a Role in CF Microbiology?     
S11-04  Reliability of Antibiotic Susceptibility Testing in CF and Relationship to Clinical Outcomes     
S12  Health Promotion and Physical Activity: Through the Ages 
S12-01  The Evidence for Exercise     
S12-02  Exercise for the Ages and Stages of CF     
S12-03  Addressing Active and Secondhand Tobacco Smoke Exposure in CF     
S12-04  Staying Healthy with CF: Beyond Airway Clearance and Enzymes     
S13  Inflammation & Airway Destruction 
S13-01  Metalloproteinases and CF Lung Disease     
S13-02  The Role of CXCR1 in CF Lung Disease     
S13-03  Proteolytic Processing and Inactivation of Innate Immune Petides in the CF Lung     
S13-04  Proteases and Sputum Markers: Do They Tell Us Anything Clinically Relevant?     
S14  Endocrine Issues in CF 
S14-01  Update on CFRD     
S14-02  Male Sex Hormones in CF and Their Role in Overall Health     
S14-03  Female Sex Hormones and Their Role in Overall Health     
S14-04  Update on Bone Mineralization in CF     
W12  CF Models — All Shapes & Sizes 
W12-01  Introduction     
W12-02  Abstract 235. Genome-wide Screening and Characterization of Modifiers of CFTR Trafficking and Function in Yeast Cell Model     
W12-03  Abstract 236. Short Hairpin RNA Knockdown in Well-differentiated Human Bronchial Epithelial Cells: A Method for Querying Gene Function Relevant to Cystic Fibrosis     
W12-04  Abstract 237. Restoration of Normal Levels of Mucus Transport to CF Human Ciliated Airway Epithelium Requires Delivery of CFTR to >45% of Ciliated Cells     
W12-05  Abstract 238. Physiological Model System for Testing Pharmacological Correctors of ∆F508 CFTR Processing in Native Murine Epithelium     
W12-06  Abstract 239. Evaluation of Airway Epithelia in CFTR -/- Piglets     
W12-07  Abstract 240. Loss of CFTR Function Specifically in the Mouse Intestinal Epithelium is Not Sufficient to Cause Reduced Growth and Survival Observed in CFTR Null Mice     
W13  Controversial Issues in Adult Care: Collaborating with Adult CF Patients 
W13-01  Introduction   
W13-02  Abstract 668. Disclosure of Chronic Disease in Adults with CF: The Adult Data for Understanding Lifestyle and Transitions (Adult) Survey     
W13-03  Abstract 670. Male Infertility in Cystic Fibrosis: An Irish Perspective     
W13-04  Abstract. 671. Sleeping in Each Morning: Is it Affecting My Cystic Fibrosis?     
W13-05  Abstract 672. Pain is a Common, Under-recognized Problem Affecting Quality of Life, Mood, and Sleep in Adults with Cystic Fibrosis     
W13-06  Abstract. 673. Adherence Barriers and Motivators: Older Teenager and Adult Perceptions of the CF Regimen     
W13-07  Abstract 674. Psychological Functioning and Quality of Life of Cystic Fibrosis Adults and Adolescents     
W14  Thinking Outside the Box: Innovations in Care That Have Improved CF Center Outcomes 
W14-01  Introduction     
W14-02  Abstract 703. Use of a Virtual Learning Collaborative to Engage a CF Team in Patient Self Management Support     
W14-03  Abstract 704. The Ins and Outs of CF Staff Education     
W14-04  Abstract 705. Does Patient Education Increase Understanding of and Adherence to Airway Clearance Techniques and Key Therapies in Adults with Cystic Fibrosis?     
W14-05  Abstract 706. Nutrition, Feeding, and Swallowing Program: Southern New Hampshire Cystic Fibrosis Home Based Nutrition Care     
W14-06  Peer Driven Education     
W14-07  Nintendo® Wii™ for Endurance Exercise in Hospitalized Children with Cystic Fibrosis     
W15  WT vs. DF508 CFTR: Structure & Interactions 
W15-01  Introduction     
W15-02  Abstract 8. SHSPS Target ΔF508 CFTR for ERAD via a SUMO-dependent Pathway     
W15-03  Abstract 9. Effects of Soluble ER Lumenal Components on Endoplasmic Reticulum-associated Degradation of CFTR     
W15-04  Abstract 10. Protein Stability and Functional Differences of ∆F508 CFTR after Low Temperature and CORR-4A Treatment     
W15-05  Abstract 11. Filamin-A Modulates CFTR Surface Expression via Filamin-A IG Repeat 21 and Interacts with the Scaffold Protein Rack1     
W15-06  Abstract 12. Characterization of Wild-type and ΔF508 NBD1 from CFTR with a Single Solubilization Mutation     
W15-07  Abstract 13. The Crystal Structure of the Second Nucleotide Binding Domain (NBD2) of CFTR Suggests NBD2 Subdomain Movements are Involved in Channel Opening     
W15-08  Discussion & Wrap-up     
W16  GI/Liver & Nutrition Research 
W16-01  Introduction   
W16-02  Abstract 608. Growth During the First Year of Life of Formula-fed and Breastfed Infants Diagnosed Through the Wisconsin Routine Newborn Screening (NBS) Program     
W16-03  Abstract 609. A New Model for Cystic Fibrosis Liver Disease     
W16-04  Abstract 610. Enteropathy — A New Finding in Cystic Fibrosis     
W16-05  Abstract 611. A Pre-Post Retrospective Study of Patients with Cystic Fibrosis and Gastrostomy Tubes     
W16-06  Abstract 612. Malabsorption Blood Test (MBT): Pilot Study to Detect the Effects of Pancreatic Enzyme Dose Titration on Fat Absorption     
W16-07  Abstract 613. A Phase III Study of the Efficacy and Safety of ALTU-135 for Treatment of Pancreatic Insufficiency in CF     
W17  Airway Clearance Techniques: Current Issues & Applications 
W17-01  Introduction     
W17-02  Abstract 513. Exercise Aids Airway Clearance by Increasing Respiratory Flow Rates and Decreasing Mucus Viscoelasticity in CF     
W17-03  Cystic Fibrosis Pulmonary Guidelines: Airway Clearance Therapies     
W17-04  Abstract 515. Experiences with Acoustic Wave Percussion     
W17-05  How to Make the Most Effective Use of High Frequency Chest Wall Compression     
W17-06  Abstract 516. Patient Demonstration of Acapella and Huff Cough to Faciltiate Education and Adherence to Airway Clearance     
W17-07  Abstract 517. The Impact of a Re-education Program for Airway Clearance Techniques (REACT) on Pulmonary Function in Patients with Cystic Fibrosis: A Two Year Follow-up. Can Outcome Measures Be Sustained?     
W17-08  Discussion & Wrap-up     
W18  Pulmonary I 
W18-01  Introduction     
W18-02  Abstract 440. Practice Patterns for Treating Respiratory Exacerbations in Cystic Fibrosis     
W18-03  Abstract 441. Optimal Spirometry Endpoints for Randomized Controlled Trials in Cystic Fibrosis: Percent Predicted or Liters?     
W18-04  Abstract 442. Treatment of Cystic Fibrosis Exacerbations Using Biofilm Antibiotic Susceptibility Testing     
W18-05  Abstract 443. AUC Protocol for Daily Dosing of IV Tobramycin     
W18-06  Abstract 444. Inhaled 7% Hypertonic Saline is Well Tolerated in Infants and Toddlers with CF     
W18-07  Abstract 445. Year-to-Year Changes in Lung Function in Individuals with Cystic Fibrosis     
W19  Host-Pathogen Interactions 
W19-01  Introduction     
W19-02  Pathogen Suppression of Host Innate Immunity     
W19-03  Abstract 339. A Combination of Tobramycin and FDA-approved Iron Chelators Disrupts Pseudomonas Aeruginosa Biofilms on Live Cystic Fibrosis Airway Cells     
W19-04  Abstract 340. Role of CFTR in RSV Susceptibility: An Inbred Mouse Model     
W19-05  Abstract 341. MAPK Regulation of CL-Secretion and Inflammatory Response to Flagellin     
W19-06  Abstract 342. Pseudomonas Aeruginosa Hemolytic Phospholipase C Regulation in Host-associated Environments     
W19-07  Abstract 343. A Transcriptome Analysis of the In Vitro Response of Pseudomonas Aeruginosa to Polymorphonuclear Leukocyte Exposure     
W20  Emerging Bioethical Topics in CF Research & Clinical Care 
W20-01  Introduction     
W20-02  Competing Priorities in Clinical Research: Balancing Needs of Patients, Investigators, and Sponsors     
W20-03  Recruitment for Cystic Fibrosis Clinical Trials: Supporting Enrollment while Avoiding Undue Influences     
W20-04  When Families Don't Do What We Want: Lack of Knowledge, Value Preference, or Desperate Goals?     
W20-05  Transplantation, the ICU, and Palliative Care: New Goals for New Lungs?     
W20-06  Discussion & Wrap-up 
W21  Ion Transport & Mucosal Function 
W21-01  Introduction     
W21-02  Abstract 88. Coupling of Alveolar to Airway Surfaces: Studies Using a Transgenic CC10/EGFP Secreted Protein in Alveolar Epithelium     
W21-03  Abstract 89. Does Ion Transport Differ in Small and Large Airways?     
W21-04  Abstract 90. Hyposecretion of Mucus in Response to Substance P in Human Cystic Fibrosis Airways     
W21-05  Abstract 91. Regulation of Mucociliary Clearance by DUOX2 and CFTR Expression and Function     
W21-06  Abstract 92. Inhibition of CFTR Mediated CL- Current by Neutrophil Elastase     
W21-07  Abstract 93. CFTR Protein Levels and Function are Reversibly Decreased by Whole Smoke Exposure in Both HBECs and BHK Cells but Channel Gating is Unaffected     
Back to Top
October 25, 2008

P3  Taking the CF Battle to the Extremes: Healthy Starts with Newborn Screening; Healthy Aging with Improved Adult Care     
S15  Interrogating the Genome & Beyond 
S15-01  Genome-wide Association Studies: An Overview and an Application to Asthma     
S15-02  Finding Genetic Modifiers of CF Lung Disease Using Genome-wide Linkage     
S15-03  Modifier Genes for CF Lung Disease: From Genome-wide SNP Scan to Biology     
S15-04  Gene Modifiers in Cystic Fibrosis: An Update     
S16  Multidisciplinary Care of Infants with CF 
S16-01  Family Education: The Foundation of Care for the Healthy CF Infant     
S16-02  Nutrition Care of Newly Diagnosed Infants with CF     
S16-03  The Expanding Role of the Clinic Physiotherapist - Beyond CPT and Into Developmental Screening     
S16-04  Establishing Balance and Equilibrium in the First Years; Every Family is Unique     
S17  Maturation of Mucins to Mucus: Relevance to CF 
S17-01  Packaging of Serglycin Proteoglycan-Protease Complexes in Mast Cells, and the Importance of these Granule Mediators in Inflammation and Innate Immunity     
S17-02  Architecture of Mucins — Is a Mucus-associated Protease a Key Player in Mucus Formation?     
S17-03  MUC5AC and MUC5B Mucin Assembly in Airway Goblet Cells     
S17-04  The Interaction of Mucins with Cilia, its Potential Importance for Mucus Clearance in the Large Airways and How it Might Play a Role in Mucus Adhesion in CF     
S18  New Therapies for CF Lung Disease: Update on Clinical Trials 
S18-01  Outcome Measures to Assess New CF Therapies: Which One to Choose?     
S18-02  The UK Cystic Fibrosis Consortium: An Update     
S18-03  Update on PTC124 Clinical Trials     
S18-04  The TIGER-1 Phase 3 Clinical Trial of Denufosol in Cystic Fibrosis     
S19  CF Antibiotic Therapy: (Maximizing Efficacy, Minimizing Toxicity) 
S19-01  Maximizing the Efficacy and Safety of Aminoglycoside Therapy     
S19-02  Maximizing the Efficacy and Safety of Colistimethate Therapy     
S19-03  Above All Do No Harm: Strategies to Reduce Antibiotic Toxicity in CF     
S19-04  Antibiotic Desensitization: A Clinician's Perspective     
S20  Microbial Interactions in the CF Lung 
S20-01  Pseudomonas-Staphylococcus Molecular Interactions Impact Antibiotic Susceptibility and Respiration in Both Species     
S20-02  Interspecies Signalling via the Stenotrophomonas maltophilia Diffusible Signal Factor Influences Biofilm Formation and Polymyxin Tolerance in Pseudomonas aeruginosa     
S20-03  Relevance of Bacterial-Fungal Interactions to CF     
S20-04  Anaerobes in Cystic Fibrosis, Pathogens or Bystanders?     
W07-06b  Benefits of a Physical Therapy Focused In-Patient Program on Outcomes in Adults with Cystic Fibrosis     
W22  Microbial Ecology & Diversity in the CF Lung 
W22-01  Introduction   
W22-02  Abstract 344. Large Scale Multiplex Sequencing for Ribosomal RNA Metagenomics From Cystic Fibrosis Airway Samples     
W22-03  Abstract 345. Analysis of Microbial Community Composition, Dynamics and Bacterial Concentration During Exacerbation in Cystic Fibrosis Patients     
W22-04  Abstract 346. Measurement of Bacterial Community Dynamics During Pulmonary Exacerbation by Quantitative Culture and Terminal Restriction Fragment Length Polymorphism (T-RFLP) Analysis     
W22-05  Abstract 347. Changing Composition and Structure of Bacteria in Cystic Fibrosis Lungs Over 400 Days     
W22-06  Abstract 348. Characterization of the Bacteriophage Community in the Airway Secretions of Normal Health Volunteers and Clinically Stable Cystic Fibrosis Patients     
W22-07  Abstract 349. Molecular Analysis Showing Diverse Respiratory Fungal Infections in South Florida Cystic Fibrosis Patients     
W22-08  Discussion & Wrap-up 
W23  Improving Nutrition Outcomes through Interdisciplinary Collaborations 
W23-01  Introduction     
W23-02  Abstract 614. Barriers to Nutritional Adherence and Family-based Solutions     
W23-03  Abstract 615. Behavior and Nutrition Treatment for Preschoolers with CF: Weight and Height Z-Score Changes Show Improvement in Growth at 4-Year Follow-up     
W23-04  The Adolescent Experience: Nutrition Expectations, Independence, and Developmental Challenges     
W23-05  Abstract 616. Use of an Exercise Survey to Identify CF Patients at Risk for Declining Pulmonary and Nutritional Status     
W23-06  The Role of the Gastroenterologist in CF Care: The Dartmouth Experience     
W23-07  The Role of the Endocrinologist in Improving Nutrition Outcomes in CF     
W23-08  Discussion & Wrap-up   
W24  Patient vs. Payer: How to Win the Reimbursement Battle   
W24-01  Introduction   
W24-02  Passport to Care: Obtaining Insurance Coverage and Payment for Care     
W24-03  Helping the CF Physician Understand Reimbursement Issues     
W24-04  One Social Worker's Mission: Coverage for All Patients     
W24-05  A CF Care Team Approach to Reimbursement of Care     
W24-06  CFF Initiatives: Making Access to Care a Priority     
W24-07  Discussion & Wrap-up   
W25  Non-invasive Ventilation in CF 
W25-01  Introduction     
W25-02  Sleep, Ventilatory Failure and NIV     
W25-03  When Should We Start NIV in CF?     
W25-04  Secretion Clearance and NIV     
W25-05  NIV to Assist Exercise in CF     
W25-06  Pro/Con: NIV in CF — Does it Matter?     
W26  Understanding & Overcoming the DF508 CFTR Processing Defect 
W26-01  Introduction     
W26-02  Misfolding and Rescue of DF508 CFTR Starts in NBD1 
W26-03  Abstract 14. Analysis of Cotranslational NBD1 Folding Using Fluorescence Resonance Energy Transfer     
W26-04  Abstract 15. Rescue of Human CFTR-DF508 Processing and Function in Human-Mouse Chimeras     
W26-05  Abstract 16. Pharmacological Stabilization of DF508 CFTR at the Cell Surface: Design of CAL-Selective PDZ Inhibitors     
W26-06  Abstract 17. Chemical Correctors VRT-532 and CORR-4A Facilitate Stabilization and Assembly of Membrane Domains Enabling CFTR to Bypass ER Quality Control Checkpoints     
W26-07  Abstract 18. Multiple Gating Defects Associated with the DF508 Mutation     
W27  Decision Making & Outcomes in Lung Transplantation 
W27-01  Introduction   
W27-02  Abstract 540. The Effect of the Lung Allocation Score on Early Outcomes in Lung Transplantation Among Individuals with Cystic Fibrosis     
W27-03  Hitting the High Points: Psychosocial Assessments in Lung Transplantation     
W27-04  Abstract 541. Caregiver Perspectives on Decision Making about Lung Transplantation in Cystic Fibrosis     
W27-05  Abstract 542. Randomized Controlled Trial of a Decision Aid for Cystic Fibrosis Patients Considering Referral for Lung Transplantation     
W27-06  Abstract 543. Anxiety and Quality of Life After Transplantation     
W27-07  Abstract 544. A Prospective Study of Health-related Quality of Life After Lung Transplant for CF     
W28  Epidemiology & Newborn Screening 
W28-01  Introduction   
W28-02  Abstract 551. Cystic Fibrosis Newborn Screening in Wisconsin: Comparison of Growth Between Children Diagnosed During the Randomized Control Trial (1985-1994) and the Routine Program (1994-2003)     
W28-03  Abstract 552. The Dilemma of the Very-High IRT, Screen-positive Infants in IRT/DNA CF Newborn Screening Programs: The New York State Experience     
W28-04  Abstract 553. Relationship of CFTR Mutation to Longitudinal Clinical Outcome in Cystic Fibrosis     
W28-05  Abstract 554. Longitudinal Assessment of Changes in Health Status and Health-related Quality of Life in Cystic Fibrosis     
W28-06  Abstract 555. Greater Hospitalization Among Females with Cystic Fibrosis is Independent of Lung Function and Nutritional Status     
W28-07  Abstract 556. Diagnosis, Patterns of Care, and Long-term Survival in Nonclassic Cystic Fibrosis     
W29  Endocrine & Bone Disease 
W29-01  Introduction     
W29-02  Abstract 647. Bone Mineral Density and Habitual Physical Activity in Cystic Fibrosis     
W29-03  Abstract 648. Very High Dose Vitamin D2 Has Short-term Effectiveness but Questionable Long-term Efficacy in the Treatment of Vitamin D Insufficiency in Pediatric CF Patients     
W29-04  Abstract 649. Murine Model for Cystic Fibrosis (CF) Bone Disease Demonstrates Sex-related Differences in Bone Formation     
W29-05  Abstract 651. Increased Inflammation Accelerates the Development of Impaired Glucose Tolerance in Patients with Cystic Fibrosis     
W29-06  Abstract 652. Recombinant Adeno-associated Virus Serotype 1 (rAAV1)-Mediated Alpha-1 Antitrypsin (AAT) Gene Therapy in a Cystic Fibrosis (CF) Related Diabetes Mouse Model     
W29-07  Abstract 653. Lipid Profiles in an Adult Cystic Fibrosis Population     
W30  End of Life: Tough Decisions 
W30-01  Introduction     
W30-02  Transplantation and Palliative Care     
W30-03  Abstract 707. A Retrospective Study of End of Life Care in Cystic Fibrosis     
W30-04  End of Life: A Husband's View     
W30-05  You Are Never Ready: Losing a Child to CF     
W30-06  Healthcare Provider's Role in Making Difficult Decisions     
W30-07  Discussion & Wrap-up     
W31  Airway Defense: Mechanisms & Outcome Measures 
W31-01  Introduction     
W31-02  Abstract 154. Factors Influencing Sputum Arginase Activity in Children with Cystic Fibrosis in Stable Disease and During Treatment of Pulmonary Exacerbation     
W31-03  Abstract 155. Agmatine is a Novel Inflammatory Agent Found in CF Sputum     
W31-04  Abstract 156. Amphiregulin: A New Candidate Biomarker of Inflammation in CF Airway     
W31-05  Abstract 157. Ibuprofen Inhibits Transcription and Secretion of Interleukin-8 in an In Vitro Model     
W31-06  Role of CFTR in Human Alveolar Macrophages on Inflammatory Response and Apoptosis     
W31-07  Abstract 158. Longitudinal Assessment of Mucociliary Clearance in CF: Repeatability and Impact of Exacerbations     
Back to Top
Demo

Demo  2008 Demo Session 
Back to Top